Heparins attenuate cancer metastasis: Are selectins the link?

Cancer Investigation

Volumn 27, Issue 5, 2009, Pages 474-481

  Läubli, Heinz ^a   Borsig, Lubor ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adhesion molecules; Glycosaminoglycans; Heparin; Metastasis; P selectin; Selectin ligands

Indexed keywords

ANTIVITAMIN K; COUMARIN DERIVATIVE; DALTEPARIN; FONDAPARINUX; HEPARANASE; HEPARIN; HIRUDIN; L SELECTIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PADGEM PROTEIN; PLACEBO; SELECTIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL INTERACTION; CLINICAL TRIAL; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; ANIMAL; CELL COMMUNICATION; DRUG EFFECT; METABOLISM; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; HEPARIN; HUMANS; MICE; NEOPLASM METASTASIS; SELECTINS;

EID: 67449085403     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802647136     Document Type: Review

References (90)

1. Prandoni, P. How I treat venous thromboembolism in patients with cancer. Blood 2005, 106(13), 4027-4033. (Pubitemid 41775905)
2. Falanga, A. Thrombophilia in cancer. Semin Thromb Hemost 2005, 31(1), 104-110.
3. Lip, G.Y.; Chin, B.S.; Blann, A.D. Cancer and the prothrombotic state. Lancet Oncol 2002, 3(1), 27-34.
4. Rickles, F.R.; Falanga, A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001, 102(6), V215-V224. (Pubitemid 32539212)
5. Varki, A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007, 110(6), 1723-1729. (Pubitemid 47443881)
6. Palumbo, J.S.; Talmage, K.E.; Massari, J.V.; La Jeunesse, C.M.; Flick, M.J.; et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007, 110(1), 133-141.
7. Ruf, W.; Mueller, B.M. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006, 32(Suppl. 1), 61-68.
8. Boccaccio, C.; Sabatino, G.; Medico, E.; Girolami, F.; Follenzi, A.; Reato, G.; Sottile, A.; Naldini, L.; Comoglio, P.M. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005, 434(7031), 396-400.
9. Denko, N.C.; Giaccia, A.J. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001, 61(3), 795-798.
10. Wahrenbrock, M.; Borsig, L.; Le, D.; Varki, N.; Varki, A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003, 112(6), 853-862. (Pubitemid 38063743)
11. Ornstein, D.L.; Zacharski, L.R. The use of heparin for treating human malignancies. Haemostasis 1999, 29(Suppl. S1), 48-60.
12. Kakkar, A.K.; Hedges, A.R.; Williamson, R.C.N.; Kakkar, V.V. Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol 1995, 6, 885-888.
13. Kuderer, N.M.; Khorana, A.A.; Lyman, G.H.; Francis, C.W. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007, 110(5), 1149-1161.
14. Tagalakis, V.; Blostein, M.; Robinson-Cohen, C.; Kahn, S.R. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 2007, 33(4), 358-368. (Pubitemid 46760529)
15. Lever, R.; Page, C.P. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002, 1(2), 140-148. (Pubitemid 41646521)
16. Zacharski, L.R.; Ornstein, D.L.; Mamourian, A.C. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000, 26(Suppl. 1), 69-77.
17. Smorenburg, S.M.; Van Noorden, C.J. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001, 53(1), 93-105. (Pubitemid 32173109)
18. Varki, N.M.; Varki, A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002, 28(1), 53-66. (Pubitemid 34194873)
19. Borsig, L.; Stevenson, J.L.; Varki, A. Heparin in cancer: role of selectin interactions. In Cancer-Associated Thrombosis, A.A. Khorana and C.W. Francis (eds.).New York, Informa Healthcare, 2007, 97-113.
20. Lebeau, B.; Chastang, C.; Brechot, J.M.; Capron, F.; Dautzenberg, B.; Delaisements, C.; Mornet, M.; Brun, J.; Hurdebourcq, J.P.; Lemarie, E. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994, 74(1), 38-45.
21. Altinbas, M.; Coskun, H.S.; Er, O.; Ozkan, M.; Eser, B.; Unal, A.; Cetin, M.; Soyuer, S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004, 2(8), 1266-1271. (Pubitemid 40186120)
22. Sideras, K.; Schaefer, P.L.; Okuno, S.H.; Sloan, J.A.; Kutteh, L.; Fitch, T.R.; Dakhil, S.R.; Levitt, R.; Alberts, S.R.; Morton, R.F.; Rowland, K.M.; Novotny, P.J.; Loprinzi, C.L. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006, 81(6), 758-767. (Pubitemid 43839491)
23. Kakkar, A.K.; Levine, M.N.; Kadziola, Z.; Lemoine, N.R.; Low, V.; Patel, H.K.; Rustin, G.; Thomas, M.; Quigley, M.; Williamson, R.C. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004, 22(10), 1944-1948.
24. Klerk, C.P.; Smorenburg, S.M.; Otten, H.M.; Lensing, A.W.; Prins, M.H.; Piovella, F.; Prandoni, P.; Bos, M.M.; Richel, D.J.; van Tienhoven, G.; Buller, H.R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005, 23(10), 2130-2135. (Pubitemid 46218704)
25. Lazo-Langner, A.; Goss, G.D.; Spaans, J.N.; Rodger, M.A. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007, 5(4), 729-737. (Pubitemid 46563571)
26. Lee, A.Y.; Levine, M.N.; Baker, R.I.; Bowden, C.; Kakkar, A.K.; Prins, M.; Rickles, F.R.; Julian, J.A.; Haley, S.; Kovacs, M.J.; Gent, M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349(2), 146-153. (Pubitemid 36818784)
27. Lee, A.Y.; Rickles, F.R.; Julian, J.A.; Gent, M.; Baker, R.I.; Bowden, C.; Kakkar, A.K.; Prins, M.; Levine, M.N. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005, 23(10), 2123-2129. (Pubitemid 46218703)
28. Lee, A.E.; Rogers, L.A.; Longcroft, J.M.; Jeffery, R.E. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic- polycytidylic acid. Clin ExpMetastasis 1990, 8(2), 165-171.
29. Kragh, M.; Binderup, L.; Vig Hjarnaa, P.J.; Bramm, E.; Johansen, K.B.; Frimundt Petersen, C. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep 2005, 14(1), 99-104.
30. Vlodavsky, I.; Mohsen, M.; Lider, O.; Svahn, C.M.; Ekre, H.P.; Vigoda, M.; Ishai-Michaeli, R.; Peretz, T. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1994, 14(1-6), 290-302.
31. Borsig, L.; Wong, R.; Feramisco, J.; Nadeau, D.R.; Varki, N.M.; Varki, A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001, 98(6), 3352-3357.
32. Borsig, L.; Wong, R.; Hynes, R.O.; Varki, N.M.; Varki, A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers ofmetastasis. Proc Natl Acad Sci USA 2002, 99(4), 2193-2198. (Pubitemid 34169037)
33. Ludwig, R.J.; Boehme, B.; Podda, M.; Henschler, R.; Jager, E.; Tandi, C.; Boehncke, W.H.; Zollner, T.M.; Kaufmann, R.; Gille, J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004, 64(8), 2743-2750. (Pubitemid 38500611)
34. Yoshitomi, Y.; Nakanishi, H.; Kusano, Y.; Munesue, S.; Oguri, K.; Tatematsu, M.; Yamashina, I.; Okayama, M. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004, 207(2), 165-174. (Pubitemid 38457037)
35. Stevenson, J.L.; Choi, S.H.; Varki, A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005, 11(19), 7003-7011. (Pubitemid 41428760)
36. Ludwig, R.J.; Alban, S.; Bistrian, R.; Boehncke, W.H.; Kaufmann, R.; Henschler, R.; Gille, J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006, 95(3), 535-540.
37. Engelberg, H. Actions of heparin that may affect the malignant process. Cancer 1999, 85(2), 257-272. (Pubitemid 29051278)
38. Folkman, J.; Shing, Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv ExpMed Biol 1992, 313, 355-364.
39. Harvey, J.R.; Mellor, P.; Eldaly, H.; Lennard, T.W.; Kirby, J.A.; Ali, S. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res 2007, 13(5), 1562-1570.
40. Mellor, P.; Harvey, J.R.; Murphy, K.J.; Pye, D.; O'Boyle, G.; Lennard, T.W.; Kirby, J.A.; Ali, S. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer 2007, 97(6), 761-768. (Pubitemid 47396282)
41. Amirkhosravi, A.; Mousa, S.A.; Amaya, M.; Francis, J.L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003, 1(9), 1972-1976.
42. Fareed, J.; Hoppensteadt, D.A.; Bick, R.L. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000, 26(Suppl 1), 5-21. (Pubitemid 30696204)
43. Zacharski, L.R.; Ornstein, D.L. Heparin and cancer. Thromb Haemost 1998, 80(1), 10-23.
44. Niers, T.M.; Klerk, C.P.; DiNisio, M.; Van Noorden, C.J.; Buller, H.R.; Reitsma, P.H.; Richel, D.J. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007, 61(3), 195-207.
45. Hostettler, N.; Naggi, A.; Torri, G.; Casu, B.; Vlodavsky, I.; Borsig, L. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007, 21(13), 3562-3572.
46. Lapierre, F.; Holme, K.; Lam, L.; Tressler, R.J.; Storm, N.; Wee, J.; Stack, R.J.; Castellot, J.; Tyrrell, D.J. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996, 6(3), 355-366.
47. Ono, K.; Ishihara, M.; Ishikawa, K.; Ozeki, Y.; Deguchi, H.; Sato, M.; Hashimoto, H.; Saito, Y.; Yura, H.; Kurita, A.; Maehara, T. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer 2002, 86(11), 1803-1812.
48. Sciumbata, T.; Caretto, P.; Pirovano, P.; Pozzi, P.; Cremonesi, P.; Galimberti, G.; Leoni, F.; Marcucci, F. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 1996, 16(3), 132-143.
49. Hu, L.; Lee, M.; Campbell, W.; Perez-Soler, R.; Karpatkin, S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004, 104(9), 2746-2751. (Pubitemid 39434957)
50. Im, J.H.; Fu, W.; Wang, H.; Bhatia, S.K.; Hammer, D.A.; Kowalska, M.A.; Muschel, R.J. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004, 64(23), 8613-8619.
51. Ilan, N.; Elkin, M.; Vlodavsky, I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006, 38(12), 2018-2039. (Pubitemid 44397619)
52. Edovitsky, E.; Elkin, M.; Zcharia, E.; Peretz, T.; Vlodavsky, I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004, 96(16), 1219-1230. (Pubitemid 39232713)
53. Miao, H.Q.; Elkin, M.; Aingorn, E.; Ishai-Michaeli, R.; Stein, C.A.; Vlodavsky, I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999, 83(3), 424-431. (Pubitemid 29455768)
54. Parish, C.R.; Freeman, C.; Brown, K.J.; Francis, D.J.; Cowden, W.B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999, 59(14), 3433-3441.
55. Honn, K.V.; Tang, D.G.; Crissman, J.D. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992, 11, 325-351.
56. Karpatkin, S.; Pearlstein, E.; Ambrogio, C.; Coller, B.S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988, 81(4), 1012-1019.
57. Nieswandt, B.; Hafner, M.; Echtenacher, B.; Mannel, D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999, 59(6), 1295-1300. (Pubitemid 29136261)
58. Tanaka, N.G.; Tohgo, A.; Ogawa, H. Platelet-aggregating activities of metastasizing tumor cells. V. In situ roles of platelets in hematogenous metastases. Invasion Met 1986, 6(4), 209-224.
59. Gasic, G.J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984, 3, 99-114.
60. Fuster, M.M.; Brown, J.R.; Wang, L.; Esko, J.D. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 2003, 63(11), 2775-2781.
61. Borsig, L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol Sci 2004, 19, 16-21. (Pubitemid 38271026)
62. Garcia, J.; Callewaert, N.; Borsig, L. P-selectin mediates metastatic progression through binding to sulfatides on carcinoma cells. Glycobiology 2007, 17(2), 185-196. (Pubitemid 46152535)
63. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420(6917), 860-867.
64. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1), 71-78.
65. Laubli, H.; Stevenson, J.L.; Varki, A.; Varki, N.M.; Borsig, L. L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 2006, 66(3), 1536-1542. (Pubitemid 43259935)
66. Kansas, G.S. Selectins and their ligands: current concepts and controversies. Blood 1996, 88, 3259-3287.
67. Lowe, J.B. Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Kidney Int 1997, 51, 1418-1426.
68. McEver, R.P. Selectin-carbohydrate interactions during inflammation and metastasis. 1997, 14(5), 585-591.
69. Kim, Y.S.; Gum, J.; Brockhausen, I, Jr. Mucin glycoproteins in neoplasia. Glycoconj J 1996, 13, 693-707.
70. Kim, Y.J.; Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997, 14(5), 569-576. (Pubitemid 27353200)
71. Yang, J.M.; Byrd, J.C.; Siddiki, B.B.; Chung, Y.S.; Okuno, M.; Sowa, M.; Kim, Y.S.; Matta, K.L.; Brockhausen, I. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology 1994, 4, 873-884.
72. Nakamori, S.; Kameyama, M.; Imaoka, S.; Furukawa, H.; Ishikawa, O.; Sasaki, Y.; Kabuto, T.; Iwanaga, T.; Matsushita, Y.; Irimura, T. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993, 53, 3632-3637. (Pubitemid 23229648)
73. Tatsumi, M.; Watanabe, A.; Sawada, H.; Yamada, Y.; Shino, Y.; Nakano, H. Immunohistochemical expression of the sialyl Lewis x antigen on gastric cancer cells correlates with the presence of liver metastasis. Clin Exp Metastasis 1998, 16(8), 743-750. (Pubitemid 29170484)
74. Ogawa, J.I.; Inoue, H.; Koide, S. alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma. Cancer 1997, 79(9), 1678-1685.
75. Ogawa, J.; Tsurumi, T.; Yamada, S.; Koide, S.; Shohtsu, A. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 1994, 73(4), 1177-1183.
76. Jorgensen, T.; Berner, A.; Kaalhus, O.; Tveter, K.J.; Danielsen, H.E.; Bryne, M. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res 1995, 55(9), 1817-1819.
77. Idikio, H.A. Sialyl-Lewis-X, Gleason grade and stage in non-metastatic human prostate cancer. Glycoconj J 1997, 14(7), 875-877. (Pubitemid 27514335)
78. Renkonen, J.; Paavonen, T.; Renkonen, R. Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer 1997, 74(3), 296-300.
79. Yamaguchi, A.; Ding, K.; Maehara, M.; Goi, T.; Nakagawara, G. Expression of nm23-H1 gene and Sialyl Lewis X antigen in breast cancer. Oncology 1998, 55(4), 357-362. (Pubitemid 28279681)
80. Bevilacqua, M.P.; Nelson, R.M. Endothelial-leukocyte adhesion molecules in inflammation and metastasis. Thromb Haemost 1993, 70(1), 152-154. (Pubitemid 23225469)
81. Slattery, M.J.; Dong, C. Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer 2003, 106(5), 713-722. (Pubitemid 36993395)
82. Wu, Q.D.; Wang, J.H.; Condron, C.; Bouchier-Hayes, D.; Redmond, H.P. Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 2001, 280(4), C814-C822. (Pubitemid 32472321)
83. Liang, S.; Sharma, A.; Peng, H.H.; Robertson, G.; Dong, C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 2007, 67(12), 5814-5820. (Pubitemid 46985015)
84. Koenig, A.; Norgard-Sumnicht, K.; Linhardt, R.; Varki, A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998, 101, 877-889. (Pubitemid 28096085)
85. Nelson, R.M.; Cecconi, O.; Roberts, W.G.; Aruffo, A.; Linhardt, R.J.; Bevilacqua, M.P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993, 82, 3253-3258.
86. Stevenson, J.L.; Varki, A.; Borsig, L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007, 120(Suppl. 2), S107-S111. (Pubitemid 350101778)
87. Fidler, I.J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990, 50, 6130-6138.
88. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2(8), 563-572.
89. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.; Hayes, D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8), 781-791. (Pubitemid 39095313)
90. Cristofanilli, M.; Hayes, D.F.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Reuben, J.M.; Doyle, G.V.; Matera, J.; Allard, W.J.; Miller, M.C.; Fritsche, H.A.; Hortobagyi, G.N.; Terstappen, L.W. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23(7), 1420-1430. (Pubitemid 46260029)